RGBP — Regen BioPharma Share Price
0.000.00%
Last trade - 00:00- $1.86m
- $2.83m
- $0.24m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -155.58% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.11 | 0.17 | 0.24 | 0.24 | 0.24 | n/a | n/a | 16.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -64.12 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Regen BioPharma Inc. is a biotechnology company. The Company is focused on developing treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. Its primary program consists of identifying small molecules that inhibit or express NR2F6 to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Directors
- Last Annual
- September 30th, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 24th, 2012
- Public Since
- September 3rd, 2014
- No. of Shareholders
- 482
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 31,554,704
- Address
- 4700 Spring Street, Suite 304, LA MESA, 91942
- Web
- https://regenbiopharmainc.com/
- Phone
- +1 6197225505
- Auditors
- BCRG Group
Upcoming Events for RGBP
Q4 2025 Regen BioPharma Inc Earnings Release
Similar to RGBP
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Regen BioPharma share price?
As of Today at 22:53 UTC, shares in Regen BioPharma are trading at $0.06. This share price information is delayed by 15 minutes.
How has the Regen BioPharma share price performed this year?
Shares in Regen BioPharma last closed at $0.06 and the price had moved by -82.39% over the past 365 days. In terms of relative price strength the Regen BioPharma share price has underperformed the S&P500 Index by -84.45% over the past year.
What are the analyst and broker recommendations for Regen BioPharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Regen BioPharma dividend yield?
Regen BioPharma does not currently pay a dividend.
Does Regen BioPharma pay a dividend?
Regen BioPharma does not currently pay a dividend.
When does Regen BioPharma next pay dividends?
Regen BioPharma does not currently pay a dividend.
How do I buy Regen BioPharma shares?
To buy shares in Regen BioPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Regen BioPharma?
As of the previous close price of $0.06, shares in Regen BioPharma had a market capitalisation of $1.86m.
Where are Regen BioPharma shares listed?
Here are the trading details for Regen BioPharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RGBP
What kind of share is Regen BioPharma?
Based on an overall assessment of its quality, value and momentum Regen BioPharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Regen BioPharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Regen BioPharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regen BioPharma. Over the past six months, its share price has underperformed the S&P500 Index by -21.77%.
As of the last closing price of $0.06, shares in Regen BioPharma were trading -29.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Regen BioPharma PE Ratio?
The Regen BioPharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Regen BioPharma?
Regen BioPharma's management team is headed by:
- David Koos - CHM